Your browser doesn't support javascript.
loading
Unintended Consequences of Immune Therapy for Immune-Mediated Diseases: Paradoxical Psoriasis and Dupilumab-Associated Musculoskeletal Syndrome.
Wallace, Elizabeth B; Hughes, Catherine D; Menon, Bina; Kirkham, Bruce.
Affiliation
  • Wallace EB; E.B. Wallace, MD, Cherry Hills Dermatology, Englewood, Colorado, USA.
  • Hughes CD; C.D. Hughes, MD, Department of Rheumatology, Tallaght University Hospital, Dublin, Ireland.
  • Menon B; B. Menon, MD, Rheumatology Department, Guy's and St Thomas' Hospital Foundation Trust, London, UK.
  • Kirkham B; B. Kirkham, MD, Rheumatology Department, Guy's and St Thomas' Hospital Foundation Trust, and Kings College London, London, UK. bruce.kirkham@gstt.nhs.uk.
J Rheumatol ; 51(Suppl 2): 70-73, 2024 Oct 01.
Article in En | MEDLINE | ID: mdl-39089826
ABSTRACT
Two presentations at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting focused on unintended consequences of immunomodulatory therapy for psoriasis (PsO). Dr. Elizabeth Wallace presented on unintended consequences of tumor necrosis factor inhibitors for treating PsO and other inflammatory disorders. These consequences include paradoxical PsO, which is defined as unexpected new PsO cases or worsening PsO symptoms seemingly induced by treatment. Dr. Bruce Kirkham focused on unintended consequences of dupilumab treatment, which can include a musculoskeletal syndrome similar to psoriatic arthritis.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Musculoskeletal Diseases / Antibodies, Monoclonal, Humanized Limits: Humans Language: En Journal: J Rheumatol Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Musculoskeletal Diseases / Antibodies, Monoclonal, Humanized Limits: Humans Language: En Journal: J Rheumatol Year: 2024 Type: Article Affiliation country: United States